Corrigendum
2020; Wiley; Volume: 9; Issue: 5 Linguagem: Alemão
10.1002/cam4.2879
ISSN2045-7634
Tópico(s)Acute Myeloid Leukemia Research
ResumoCancer MedicineVolume 9, Issue 5 p. 1951-1951 CORRIGENDUM Open Access Corrigendum This article corrects the following: Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute – Mexico, from 2000 to 2016 Jimena Ylescas-Soria Alfredo H. de la Torre-Lujan Luis A. Herrera Daniela Miranda Flavio Grimaldo Silvia Rivas Eduardo Cervera Abelardo Meneses-García Fidias E. Leon-Sarmiento Diddier Prada Volume 8Issue 6Cancer Medicine pages: 2942-2949 First Published online: May 2, 2019 First published: 24 January 2020 https://doi.org/10.1002/cam4.2879 AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinked InRedditWechat In the article by Ylescas-Soria et al.,1 the Acknowledgments section was inadvertently omitted. It should be as follows: ACKNOWLEDGMENTS We thank Clementina Castro, MA in Basic Biomedical Research, for the critical revision of this manuscript. We also thank the Max Foundation for the management of the CML program and also Novartis Mexico for the support with imatinib for CML patients. This work was supported by the National Institutes of Health [Grant R21ES027087] and by CONACYT (Consejo Nacional de Ciencia y Tecnología – México) – FOSISS (Fondo Sectorial de Investigación en Salud y Seguridad Social SS/IMSS/ISSSTE-CONACYT) [Grant 289503]. The authors apologize for this error. REFERENCE 1Ylescas-Soria J, de la Torre-Lujan AH, Herrera LA, et al. Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute – Mexico, from 2000 to 2016. Cancer Med. 2019; 8: 2942– 2949. https://doi.org/10.1002/cam4.2201. Wiley Online Library CAS PubMed Web of Science®Google Scholar Volume9, Issue5March 2020Pages 1951-1951 ReferencesRelatedInformation
Referência(s)